Nuclear beta-catenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer

Diagnostic Pathology

Ying Liu²  Yejun Qin²  Hui Liang¹  Hongxia Cheng² 

[1] Department of otolaryngology, Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, Shandong, People's Republic of China;Department of Pathology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, People's Republic of China

关键词: Sentinel lymph node;    Liver metastasis;    Colorectal cancer;    Beta-catenin;   

Others  :  808209
DOI  :  10.1186/1746-1596-6-109

 received in 2011-09-28, accepted in 2011-11-04,  发布年份 2011

【 摘 要 】

Background

Beta-catenin, a component of the Wingless/Wnt signaling pathway, can activate target genes linking with the adenomatous polyposis coli (APC) gene in colorectal cancer. The purpose of this study is to investigate whether nuclear beta-catenin overexpression in metastatic sentinel lymph node(s) [SLN(s)] is associated with synchronous liver metastasis.

Methods

Clinicopathological data from 355 patients (93 cases with liver metastasis and 262 cases without liver metastasis) were reviewed. Beta-catenin expression in metastatic SLN(s) and liver metastatic lesions was examined by immunohistochemistry. The association of nuclear beta-catenin expression in metastatic SLN(s) and liver metastatic lesions was evaluated, and the relationship between nuclear beta-catenin expression and clinicopathological characteristics was analyzed. Finally, univariate and logistic multivariate regression analyses were adopted to discriminate the risk factors of liver metastasis.

Results

Nuclear beta-catenin overexpression in metastatic SLN(s) was observed in 70 patients with liver metastasis and 31 patients without liver metastasis (75.3% vs. 11.8%; P < 0.001). Nuclear beta-catenin expression was noted in all the metastatic lesions. Spearman rank correlation analysis demonstrated that nuclear beta-catenin expression in metastatic SLN(s) had a positive correlation with that in metastatic lesions (r = 0.425, P < 0.001). Univariate and multivariate analyses indicated that nuclear beta-catenin overexpression in metastatic SLN(s) correlated with liver metastasis.

Conclusions

Nuclear beta-catenin overexpression in metastatic SLN(s) is strongly associated with liver metastasis and may contribute to predict liver metastasis.

【 授权许可】

   
2011 Cheng et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E: Cancer statistics 2004. CA Cancer J Clin 2004, 54:8-29.
• [2]Laffer UT, Metzger U: Intraportal chemotherapy for colorectal hepatic metastases. World J Surg 1995, 19:246-51.
• [3]Barozzi C, Ravaioli M, D'Errico A, Grazi GL, Poggioli G, Cavrini G, et al.: Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 2002, 94:647-57.
• [4]Chen Z, Li M, Yuan Y, Wang Q, Yan L, Gu J: Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. Dis Colon Rectum 2010, 53:31-8.
• [5]Iwaya K, Oikawa K, Semba S, Tsuchiya B, Mukai Y, Otsubo T, et al.: Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma. Cancer Sci 2007, 98:992-9.
• [6]Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, et al.: Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003, 64:61-73.
• [7]Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Inomata M, et al.: Risk factors for early extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma. Hepatogastroenterology 2005, 52:1840-4.
• [8]Talbot IC, Ritchie S, Leighton MH, Hughes AO, Bussey HJ, Morson BC: The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980, 67:439-42.
• [9]Yamazoe Y, Maetani S, Onodera H, Nishikawa T, Tobe T: Histopathological prediction of liver metastasis after curative resection of colorectal cancer. Surg Oncol 1992, 1:237-44.
• [10]Adachi Y, Inomata M, Kakisako K, Sato K, Shiraishi N, Kitano S: Histopathologic characteristics of colorectal cancer with liver metastasis. Dis Colon Rectum 1999, 42:1053-6.
• [11]De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, et al.: Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998, 28:971-9.
• [12]Nanashima A, Yamaguchi H, Sawai T, Yasutake T, Tsuji T, Jibiki M, et al.: Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol 1999, 14:1004-9.
• [13]Fujita S, Taniguchi H, Yao T, Shimoda T, Ueno H, Hirai T, et al.: Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression. Int J Colorectal Dis 2010, 25:681-6.
• [14]Ohji Y, Yao T, Eguchi T, Yamada T, Hirahashi M, Iida M, et al.: Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: multivariate analysis of clinicopathological and immunohistochemical factors. Oncol Rep 2007, 17:525-30.
• [15]Brabletz S, Schmalhofer O, Brabletz T: Gastrointestinal stem cells in development and cancer. J Pathol 2009, 217:307-17.
• [16]Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T: Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005, 5:744-9.
• [17]Fodde R, Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007, 19:150-8.
• [18]Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al.: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001, 98:10356-61.
• [19]Harris TJ, Peifer M: Decisions, decisions: beta-catenin chooses between adhesion and transcription. Trends Cell Biol 2005, 15:234-7.
• [20]van EJH, Barker N, Clevers H: You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 2003, 13:28-33.
• [21]Bandapalli OR, Dihlmann S, Helwa R, Macher-Goeppinger S, Weitz J, Schirmacher P, et al.: Transcriptional activation of the beta-catenin gene at the invasion front of colorectal liver metastases. J Pathol 2009, 218:370-9.
• [22]Bagaria SP, Faries MB, Morton DL: Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol 2010, 101:669-76.
• [23]van AAC, Voit CA, Verhoef C, Eggermont AM: New developments in sentinel node staging in melanoma: controversies and alternatives. Curr Opin Oncol 2010, 22:169-77.
• [24]Kelley MC, Hansen N, McMasters KM: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Am J Surg 2004, 188:49-61.
• [25]Newman EA, Newman LA: Lymphatic mapping techniques and sentinel lymph node biopsy in breast cancer. Surg Clin North Am 2007, 87:353-64. viii
• [26]Bembenek A, Gretschel S, Schlag PM: Sentinel lymph node biopsy for gastrointestinal cancers. J Surg Oncol 2007, 96:342-52.
• [27]Dionigi G, Castano P, Rovera F, Boni L, Annoni M, Villa F, et al.: The application of sentinel lymph node mapping in colon cancer. Surg Oncol 2007, 16(Suppl 1):S129-32.
• [28]Bilchik AJ, Giuliano A, Essner R, Bostick P, Kelemen P, Foshag LJ, et al.: Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 1998, 4:351-8.
• [29]Dragan R, Nebojsa M, Dejan S, Ivan P, Dragos S, Damir J, et al.: Clinical application of sentinel lymph node biopsy for staging, treatment and prognosis of colon and gastric cancer. Hepatogastroenterology 2009, 56:1606-11.
• [30]He ZY, Wen H, Shi CB, Wang J: Up-regulation of hnRNP A1, Ezrin, tubulin beta-2C and Annexin A1 in sentinel lymph nodes of colorectal cancer. World J Gastroenterol 2010, 16:4670-6.
• [31]Greene FL, Page DL: AJCC Cancer Staging Manual. 6th edition. New York, NY: Springer-Verlag; 2002:127-38.
• [32]Smith FM, Coffey JC, Khasri NM, Walsh MF, Parfrey N, Gaffney E, et al.: Sentinel nodes are identifiable in formalin-fixed specimens after surgeon-performed ex vivo sentinel lymph node mapping in colorectal cancer. Ann Surg Oncol 2005, 12:504-9.
• [33]Romeo S, Bovee JV, Grogan SP, Taminiau AH, Eilers PH, Cleton-Jansen AM, et al.: Chondromyxoid fibroma resembles in vitro chondrogenesis, but differs in expression of signalling molecules. J Pathol 2005, 206:135-42.
• [34]Brembeck FH, Rosario M, Birchmeier W: Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006, 16:51-9.
• [35]Brabletz T, Jung A, Kirchner T: Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch 2002, 441:1-11.
• [36]Canavese G, Bernardi A, Candelaresi G, Lovadina P, Amerio S, Rossetti V, et al.: Expression of the E-cadherin-catenins complex in sentinel node is related to tumor morphology but not to spread to nonsentinel nodes. Pathol Res Pract 2007, 203:517-23.
• [37]Zhang B, Ougolkov A, Yamashita K, Takahashi Y, Mai M, Minamoto T: beta-Catenin and ras oncogenes detect most human colorectal cancer. Clin Cancer Res 2003, 9:3073-9.
• [38]Baldus SE, Monig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K, et al.: MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 2004, 10:2790-6.
• [39]da FLM, da LMM, Lacerda-Filho A, Cabral MM, da SRG: Colorectal carcinoma in different age groups: A histopathological analysis. Int J Colorectal Dis 2011, in press.
• [40]O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Ko CY: Are survival rates different for young and older patients with rectal cancer. Dis Colon Rectum 2004, 47:2064-9.
• [41]Liang H, Wang XN, Wang BG, Pan Y, Liu N, Wang DC, et al.: Prognostic factors of young patients with colon cancer after surgery. World J Gastroenterol 2006, 12:1458-62.
• [42]Savas N, Dagli U, Akbulut S, Yuksel O, Sahin OB: Colorectal cancer localization in young patients: should we expand the screening program. Dig Dis Sci 2007, 52:798-802.